Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following? -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (741)	10/2/2003 7:22:52 AM
From: nigel bates	Respond to of 2240

Medarex and Trillium Therapeutics Announce Collaboration to Develop Fully Human Antibody Therapeutics PRINCETON, N.J., and TORONTO, Oct. 2 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX - News) and Trillium Therapeutics Inc. (TTI), a privately-held Canadian biotechnology company, today announced a collaboration for the development of fully human antibody therapeutics. Medarex plans to use its UltiMAb Human Antibody Development System(SM) to generate antibodies to disease targets identified by TTI. Under the agreement, the two companies expect to share equally the cost and responsibility of the development of antibody products. In addition, the two companies plan to jointly commercialize and share equally future revenues arising from any antibody products resulting from this collaboration. "This collaboration with Medarex, a leader in the field of monoclonal antibody therapeutics, is a testament to the high quality of TTI's science," stated Niclas Stiernholm, Chief Executive Officer of TTI. "Moreover, it brings us an experienced antibody development partner with a broad global industry network, which is invaluable to a young company like TTI." "We are pleased to ally with TTI. We believe TTI's expertise in the area of immune-mediated disorders nicely complements Medarex's development capabilities. TTI has provided a promising target to kick-off this collaboration, and I am hopeful that the alliance will be fruitful," said Donald L. Drakeman, President and CEO of Medarex. About Trillium Therapeutics Inc. TTI, a privately held research and development company, specializes in the development of innovative therapies that restore balance to the immune system in conditions associated with aberrant and harmful immune responses, such as autoimmune and inflammatory disorders, graft rejection and viral hepatitis. TTI identifies therapeutic candidates with promising preclinical profiles and advances these into clinical testing, with the primary objective of demonstrating safety and efficacy in humans. TTI has two lead development candidates, a CD200 fusion protein (CD200Fc) and an Fgl2-specific monoclonal antibody (Fgl2 MAb), as well as several research programs. TTI collaborates extensively with research scientists at internationally renowned academic institutions, and with several major pharmaceutical and biotechnology companies. For further information, please visit the TTI Web site at www.trilliumtherapeutics.com .

To: Icebrg who wrote (741)	10/8/2003 10:52:00 AM
From: Icebrg	Read Replies (1) \| Respond to of 2240

>>Still to come this year: - EGF fusion protein - anti-anginogenesis product - colon cancer product.>> With some help from Denmark the anti-anginogenesis mAb has been identified. OGS writes the following on their website: MDX-OGS-1 The MDX-OGS-1 programme, conducted in collaboration with Medarex, is the lead programme at OGS designed to develop a fully human anti-Heparanase 1 antibody. As part of this programme, Medarex UltiMAb human antibody development system has been employed to generate antibody lead candidates that have been screened and characterised using unique assays designed by OGS. MDX-OGS-1, the first antibody product that binds to and neutralises the Heparanase 1enzyme, is expected to enter clinical trials in 2003. ogs.com It should perhaps be mentioned that there are three parties involved in this development. Apart from MEDX and OGS there is also participation from Genmab. Erik